Insights

Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operations under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

October 12, 2015

Challenges and Opportunities in CAR-T Therapy

The upcoming CAR-T Summit in Boston (November 12-13) is an opportunity for leaders from pharma, biotech and academia to get together to discuss “clinical strategy, ...

October 1, 2015

What can Automation do for Your Cell Therapy?

Automation is not just a buzzword. Automation—the act of taking laborious, manual steps of cell therapy manufacturing and making them more efficient through elimination ...

September 26, 2015

PCT and Invetech experts lead webinar on Building Deliverable Cell Therapeutics for ISCT

ISCT hosted a webinar, titled "Building Deliverable Cell Therapeutics: A Methodical Approach to Manufacturing Development," featuring experts from PCT on October 22, ...

September 15, 2015

Spreading the Word on the Future of Commercial Cell Therapy Manufacturing– PCT Heads to IBC

At the end of this month, two of my colleagues and I have the opportunity to speak at the IBC Life Sciences Cell Therapy Bioprocessing and Commercialization Conference ...

September 9, 2015

The Evolution of the Commercial Manufacturing Facility for Cell Therapy

The following is an excerpt of a commentary originally published in the September issue of DDNews, entitled, “Building a Problem or a Solution? : Removing the ...

August 4, 2015

Bridging the Gap with Chimeric Antigen Receptors

Cell therapies armed with crafted weaponry in the form of CARs (Chimeric antigen receptors) and engineered TCRs (T cell receptors) have taken immuno-oncology to a new ...

July 29, 2015

Technology Transfer in Cell Therapy Manufacturing: Critical Aspects for Success

Below is an excerpt on technology transfer in cell therapy manufacturing, written by Catherine McIntyre, PhD, Director, Technical Operations, and Cenk Sumen, PhD, ...

July 27, 2015

Development by Design Principles in Cell Therapy Manufacturing

As discussed in my previous post, FDA has provided guidance via ICH Q8 for pharmaceutical development (where Quality by Design (QbD) principles are presented) for ...

July 14, 2015

Understanding Technology Transfer, a Critical Aspect of Cell Therapy Manufacturing

Below is an excerpt on technology transfer in cell therapy manufacturing originally published in the April 2015 issue of BioProcess International as part of the article, ...

Previous All Posts Next